|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0036043,
umls-concept:C0036525,
umls-concept:C0040808,
umls-concept:C0040811,
umls-concept:C0069717,
umls-concept:C0596581,
umls-concept:C0796392,
umls-concept:C1274040,
umls-concept:C1522484,
umls-concept:C1527249,
umls-concept:C1708063,
umls-concept:C2603343
|
|
pubmed:issue |
21
|
|
pubmed:dateCreated |
2008-7-21
|
|
pubmed:abstractText |
To evaluate the safety and efficacy of three oxaliplatin and fluoropyrimidine regimens, with or without bevacizumab, as first-line treatment for metastatic colorectal cancer (CRC).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin,
http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab,
http://linkedlifedata.com/resource/pubmed/chemical/capecitabine,
http://linkedlifedata.com/resource/pubmed/chemical/oxaliplatin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:AbubakrYousifY,
pubmed-author:ChildsBarrett HBH,
pubmed-author:CohnAllen LAL,
pubmed-author:FehrenbacherLouisL,
pubmed-author:HainsworthJohn DJD,
pubmed-author:HartLowell LLL,
pubmed-author:HedrickEricE,
pubmed-author:HochsterHoward SHS,
pubmed-author:RamanathanRamesh KRK,
pubmed-author:SaifM WasifMW,
pubmed-author:SchwartzbergLeeL,
pubmed-author:WongLucasL
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3523-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18640933-Adenocarcinoma,
pubmed-meshheading:18640933-Adult,
pubmed-meshheading:18640933-Aged,
pubmed-meshheading:18640933-Aged, 80 and over,
pubmed-meshheading:18640933-Antibodies, Monoclonal,
pubmed-meshheading:18640933-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:18640933-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18640933-Colorectal Neoplasms,
pubmed-meshheading:18640933-Deoxycytidine,
pubmed-meshheading:18640933-Female,
pubmed-meshheading:18640933-Fluorouracil,
pubmed-meshheading:18640933-Humans,
pubmed-meshheading:18640933-Kaplan-Meier Estimate,
pubmed-meshheading:18640933-Leucovorin,
pubmed-meshheading:18640933-Male,
pubmed-meshheading:18640933-Middle Aged,
pubmed-meshheading:18640933-Organoplatinum Compounds
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
|
|
pubmed:affiliation |
New York University Cancer Institute, 160 East 34th St, New York, NY 10016, USA. Howard.Hochster@med.nyu.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study
|
